• Wondering if IRADIMED at around US$86.74 is still offering value or if you are late to the story? This article breaks down what the current price might be implying.
• The stock has moved 4.0% over the last 7 days, while the 30 day and year to date returns are 7.2% and 9.2% declines, set against a 67.1% return over 1 year, 95.7% over 3 years and 236.4% over 5 years.
• Recent coverage has focused on IRADIMED as part of broader evergreen interest in medical equipment stocks, with attention on how its share price history compares with fundamentals and peers over multiple time frames. This context helps explain why investors are rechecking whether the long term share price record still lines up with the underlying business.
• Right now the Simply Wall St valuation model gives IRADIMED a value score of 2 out of 6. The rest of this article will walk through the main valuation frameworks used to assess that score, before circling back to a broader way of thinking about what the stock might be worth overall.

IRADIMED scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: IRADIMED Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those amounts back to today, to arrive at an implied value per share.

For IRADIMED, the model here is a 2 Stage Free Cash Flow to Equity approach using cash flows in US$. The latest twelve month Free Cash Flow (FCF) is about $21.7 million. Analysts provide explicit FCF estimates for the earlier years, and Simply Wall St then extrapolates further out, with projected FCF reaching $32.6 million in 2030 and continuing with additional estimated figures through 2035.

When all those projected cash flows are discounted back and summed, the model arrives at an estimated intrinsic value of about $63.59 per share. Compared with a current share price close to $86.74, the DCF indicates IRADIMED is around 36.4% overvalued based on these assumptions.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests IRADIMED may be overvalued by 36.4%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: IRADIMED Price vs Earnings

For profitable companies, the P/E ratio is often a useful shorthand because it links what you are paying directly to the earnings the business is generating today. A higher P/E usually reflects higher growth expectations or lower perceived risk, while a lower P/E can point to more muted growth assumptions or higher perceived risk.

IRADIMED currently trades on a P/E of 46.96x. This sits above the Medical Equipment industry average P/E of 24.14x, although below the peer group average of 54.27x. To go a step further, Simply Wall St calculates a proprietary “Fair Ratio” for the P/E, which in this case is 19.57x. This Fair Ratio reflects factors such as IRADIMED’s earnings growth profile, profit margins, industry, market cap and specific risk characteristics, rather than relying only on simple peer or industry comparisons.

Because the Fair Ratio is tailored to the company’s own fundamentals and risk, it can offer a more rounded reference point than headline averages. Comparing the current P/E of 46.96x with the Fair Ratio of 19.57x suggests the stock is trading on a materially richer multiple than this model would imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your IRADIMED Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of IRADIMED, including assumptions on its future revenue, earnings and margins, to a financial forecast, a fair value, and finally a buy or sell decision. You can then compare that fair value with the current price, all inside an easy tool on the Community page that updates automatically when new information such as earnings or guidance arrives. For example, a bullish investor who agrees with the analyst fair value of US$118.67 and expects the company to sustain margins near 28.08% and revenue growth around 13.05% will naturally land on a higher fair value narrative than a cautious investor who focuses on risks like the narrow product range, supply chain pressures or backlog execution, and assigns more conservative assumptions that produce a lower fair value and a very different conclusion about whether the current price near recent trading levels still fits their story.

Do you think there's more to the story for IRADIMED? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.